Supernus Pharmaceuticals

Key points:

The stock is breaking out from a five-week flat base, turning actionable. We recommend adding to shares here. Support is at the rising 50-DMA (~$53.50).

Technical ratings: RS line is at a new high, RS Rating 92, A/D Rating B+.

Fundamental ratings: EPS Rank 99, SMR Rating A, Composite Rating 99.

Vertex Pharmaceuticals

Key points:

VRTX is actionable today after gapping up through near-term resistance at ~$160. The next level of resistance is all-time highs at $178.25. Underwhelming data from competitor Galapagos (GLPG) removed a major overhang on VRTX shares and will lead to upward revisions on long-term models. Consensus currently calls for 2021 adjusted EPS of $9.21 on revenue of $5.35B.

Technical ratings: RS line is now sharply rising, RS Rating of 44 will improve at the close, and A/D Rating has moved from E to D+ with today’s gap up.

Fundamental ratings: EPS Rank 74, SMR Rating A, Composite Rating 67.

Swedish Orphan Biovitrum

The stock is building the right side of a seven-week flat base. We recommend adding to current positions here. Support is the rising 50-DMA. Resistance is SEK 194.75.

Technical ratings: RS line is at an all-time high, RS Rating of 93, and A/D Rating of B.

Fundamental ratings: EPS Rank of 99, SMR Rating of A, and Composite Rating of 98

PRA Health Sciences

Key points from the report:

  • The stock cleared above resistance at $90, turning actionable. We recommend buying shares here as the stock forms the right side of a 20-week consolidation.
  • Support is at $80 and resistance is at ~$96.
  • Technical ratings: Rising RS line, RS Rating of 65, and A/D Rating of C+ (improving over the last six weeks).
  • Fundamental ratings: EPS Rank of 96, SMR Rating of A, and Composite Rating of 94.

Edwards Lifesciences

The stock is currently actionable as it breaks above resistance at $140. We recommend buying now and adding to positions as the stock clears above $143.22. Technical ratings: RS line trending higher, RS Rating 75, A/D Rating D+, but improving over the last month. Fundamental ratings: EPS Rank 94, SMR Rating A, Composite Rating 94.